The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
811
February 9, 1990
View Complete Issue         Table of Contents 2019 
Mefloquine for Malaria
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Mefloquine for Malaria
February 9, 1990 (Issue: 811)
Mefloquine hydrochloride (Lariam - Roche), a new antimalarial drug chemically related to quinine, has been approved by the US Food and Drug Administration (FDA) for prevention and treatment of Plasmodium falciparum and P. vivax malaria.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Mefloquine for Malaria
Article code: 811b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.